Senti Bio Secures $2.5M Celadon Equity Commitment, Completes $2.0M NSG Note Tranche
SNTI is trading near its 52-week low of $0.331 (3.7% above the low) on light trading volume (0.2× avg).
Summary
Senti Bio secured a $2.5M equity commitment from Celadon affiliate CPIF II-9 Limited and completed a $2.0M convertible note tranche from NSG BioInnovation Fund, both tied to the pending merger.
Key Events · Financing and Capital Events · SNTI
-
Celadon Equity Commitment
CPIF II-9 Limited committed to purchase $2.5M of common stock at the Nasdaq Minimum Price, contingent on merger closing and Nasdaq compliance plan submission.
-
NSG Note Tranche Completed
Senti Holdings completed issuance of $2.0M in Senior Secured Convertible Notes to NSG BioInnovation Fund under the amended Securities Purchase Agreement.
-
Financing Conditions
Equity commitment requires company to retain at least $600,000 in cash post-closing and take steps to maintain Nasdaq listing.
-
Merger Timeline
Equity commitment terminates if merger closes and funds in full, or by December 31, 2026 outside date.
Analysis · SNTI · Life Sciences
A $2.5 million equity commitment from Celadon affiliate CPIF II-9 Limited, priced at the Nasdaq Minimum Price and contingent on the pending merger closing, provides a new financing lifeline for a company with cash only into Q4 2026. The same day, the $2.0 million NSG convertible note tranche was completed. However, the equity commitment comes with conditions including Nasdaq compliance and $600,000 minimum cash retention. The stock trades near its 52-week low at $0.3428, and the company faces two Nasdaq delisting notices.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.33 to $2.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.